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In recent years, management of hepatitis C virus (HCV)
infection has changed dramatically because of the approval
of new antiviral therapies. The purpose of the American So-
ciety for Blood and Marrow Transplantation (ASBMT) Task
Force on HCV infection in hematopoietic cell transplant
(HCT) recipients is to provide guidance regarding diagnosis
and management of HCV infection in donors and recipients
of hematopoietic cells.
Limited data are available on treating HCV infection in
HCT recipients. A group of experts in infectious diseases,
hepatology, and HCT worked together to compile this
document with 2 goals: to summarize the currently available
data in the ﬁeld and to provide evidence-based and expert
opinion recommendations regarding early identiﬁcation and
treatment of HCV-infected donors and recipients to mini-
mize barriers to HCT and improve care and outcomes in this
population. In preparing this report, the committee recog-
nizes that in the absence of data in donors and recipientsedgments on page 1881.
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ty for Blood and Marrow Transplantation.liminary guidance while awaiting the completion of appro-
priate studies.
The recommendations herein are based on synthesis of
limited evidence, theoretical rationales, practical consider-
ations, and author opinion. When appropriate, the level of
the evidence and the strength of the recommendation have
been rated by applying the system used for the Hepatitis C
Guidance of the American Association for the Study of Liver
Diseases (AASLD) and Infectious Diseases Society of America
(IDSA) (http://hcvguidelines.org) (Table 1) [1]. However, for
some individual recommendations, the level of the sup-
porting evidence and strength of the recommendation could
not be rated.
For this report, HCT is deﬁned as transplant of any blood-
or marrow-derived hematopoietic progenitor cells,
regardless of whether the transplant is allogeneic or
autologous and regardless of the cell source (ie, bone
marrow, peripheral blood, or umbilical cord blood). The
recommendations in this document are based on data from
the following sources: research published in the peer-
reviewed literature or presented at major national and in-
ternational scientiﬁc conferences, safety warnings from the
US Food and Drug Administration (FDA) or other regulatory
agencies or from manufacturers, drug interaction data, and
prescribing information for FDA-approved products.
Table 1
Grading System used to Rate the Level of the Evidence and Strength of the Recommendation for Each Recommendation
Classiﬁcation Description
Class I Conditions for which there is evidence and/or general agreement that a given diagnostic evaluation, procedure, or treatment is
beneﬁcial, useful, and effective
Class II Conditions for which there is conﬂicting evidence and/or a divergence of opinion about the usefulness and efﬁcacy of a diagnostic
evaluation, procedure, or treatment
Class IIa Weight of evidence and/or opinion is in favor of usefulness and efﬁcacy
Class IIb Usefulness and efﬁcacy are less well established by evidence and/or opinion
Class III Conditions for which there is evidence and/or general agreement that a diagnostic evaluation, procedure, or treatment is not useful
and effective or if it in some cases may be harmful
Level of Evidence Description
Level A* Data derived from multiple randomized clinical trials, meta-analyses, or equivalent
Level B* Data derived from a single randomized trial, nonrandomized studies, or equivalent
Level C Consensus opinion of experts, case studies, or standard of care
Recommendations are based on scientiﬁc evidence and expert opinion. Each recommended statement includes a Roman numeral (I, II, or III) that represents the
level of the evidence that supports the recommendation and a letter (A, B, or C) that represents the strength of the recommendation.
* In some situations, such as for IFN-sparing HCV treatments, randomized clinical trials with an existing standard-of-care arm cannot ethically or practicably
be conducted. The FDA has suggested alternative study designs, including historical control subject or immediate versus deferred, placebo-controlled trials. For
additional examples and deﬁnitions see the FDA link (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM225333.pdf). In those instances for which there was a single predetermined, FDA-approved equivalency established, panel members considered the evi-
dence as equivalent to a randomized controlled trial for levels A or B. Adapted from the American College of Cardiology and the American Heart Association
Practice Guidelines. (American Heart Association, 2011); (Shiffman, 2003)
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headings and free text terms combined to maximize
retrieval of relevant citations from the PubMed, Scopus,
EMBASE, and Web of Science databases; search terms
included “HCV and Bone Marrow Cell Transplantation” and
“HCV and Hematopoietic Stem Cell Transplantation.” Only
articles published in English from 1990 to the present were
considered for inclusion. The ASBMT Task Force on HCV
Infection plans to review these recommendations periodi-
cally and update them to include advances in the published
evidence.EXECUTIVE SUMMARY
For more than a decade the mainstay of treatment for
HCV infection was a combination regimen of pegylated
interferon (IFN) and ribavirin, but this regimen was associ-
ated with a poor rate of sustained virologic response (SVR)
and poor tolerability, especially in cancer patients and HCT
recipients [2,3]. Furthermore, almost 30% of infected HCT
recipients could not be treated with pegylated IFN and
ribavirin because of contraindications to the treatment
combination [3]. The management of HCV infection in the
general population has recently changed as a result of FDA
approval of several direct-acting antiviral agents (DAAs),
which have rendered IFN-containing regimens obsolete for
almost all HCV genotypes.
This report, developed by the ASBMT Task Force on HCV
Infection, is speciﬁcally devoted to diagnosis and manage-
ment of HCV infection in donors and HCT candidates and
recipients. There are few data that answer important clinical
questions for such donors or recipients. The online document
from the AASLD-IDSA, “Recommendations for Testing,
Managing, and Treating Hepatitis C” (http://www.hcvgui-
delines.org), which is updated regularly throughout the year,
was used as a resource in the development of this report but
had no speciﬁc recommendations for these populations.
Thus, this document was developed to provide expert
opinion for clinicians who must make management de-
cisions while awaiting adequately powered trials dealing
with donors and HCT recipients.
Evidence is summarized, and, where possible, recom-
mendations are provided. This report replaces the 2009ASBMT-IDSA guideline [4]. Several topics are new or
expanded from that document (Table 2).NATURAL HISTORY OF HCV INFECTION IN HCT
RECIPIENTS
George B. McDonald, Marcos De Lima
Recommendations
 In all HCT survivors with active HCV infection, cofactors
that can lead to ﬁbrosis should be addressed. Patients
should be counseled to avoid excessive weight gain,
ethanol andmedications or herbal supplements that are
hepatotoxic, as well as on treatment of other causes of
liver disease (nonalcoholic fatty liver disease, hepatitis B
virus,HIV, andextrahepatic obstruction) (class I, level C),
and mobilization of excess iron (class II, level C).
 All HCV-infected long-term HCT survivors should be
evaluated for progression of liver disease every 6 to
12 months with a hepatic function panel, complete
blood cell count, and evaluation of prothrombin time/
international normalized ratio (class I, level C). If
ﬁbrosis is suspected in long-term HCT survivors,
noninvasive tests such as serologic panels and transient
elastography can be used to evaluate for the presence of
advanced ﬁbrosis (Scoring System for Histological Stage
Metavir score  F3) and cirrhosis (Metavir score F4).
 HCV-infected HCT recipients should be vaccinated
against hepatitis A virus and hepatitis B virus following
HCT immunization protocols [4].
 Donors and HCT candidates with HCV infection should
be counseled to use appropriate precautions to prevent
transmission of HCV to others (class I, level C).
 For HCV-infected HCT long-term survivors with
advanced ﬁbrosis (Metavir score  F3), surveillance for
hepatocellular carcinoma (HCC) with ultrasonography
every 6 months is recommended (class I, level C). For
patients with cirrhosis, endoscopic surveillance for
esophageal varices is recommended (class I, level A).
 HCT recipients who develop end-stage liver disease can
be considered for liver transplant; in rare cases, a living
donor liver transplant from the original hematopoietic
cell donor may be feasible (class I, level C).
Table 2
Summary of Changes Compared with the Guidelines Published in 2009 [4]
Major Change Starting Page
Updated background on natural history of HCV infection in HCT recipients 2
New recommendations regarding HCV screening:
1. Screening of all hematopoietic cell donors within 30 days before cell harvest with FDA-approved HCV antibody and RNA testing in
accordance with the FACT standards and FDA guidance (class I, level C)
3
2. Screening of all long-term survivors of HCT, especially those with epidemiologic risk factors including those transplanted in the
era before routine donor and blood product screening (class I, level C)
Updated background on impact of HCV infection on eligibility to donate hematopoietic cells or undergo HCT 4 (Table 3)
New section regarding monitoring of HCV in chronically infected HCT recipients:
1. ALT level should be evaluated at entry into care, 2 to 8 weeks after completion of the conditioning regimen, every 2 to 8 weeks
during maintenance chemotherapy or immunosuppressive treatment, and every 3 to 6 months thereafter (class II, level C)
6
2. In HCT recipients with chronic HCV infection, routine monitoring of HCV RNA is not recommended. However, viral load should be
considered for patients who have an unexplained elevation of ALT (class II, level C). HCV RNA should be measured in all patients
at entry into care, andmonitoring of viral load should be performed in patients receiving HCV treatment according to the AASLD-
IDSA HCV guidance (http://www.hcvguidelines.org/) (class I, level C).
New section regarding ﬁbrosis assessment in HCV-infected HCT candidates and recipients using serologic markers and ultrasound-
based VCTE
7
New recommendations regarding antiviral therapy for donors and HCT candidates and recipients:
1. Timing of antiviral therapy 7
2. Treatment interruption is not recommended (class I, level C) 8
3. IFN-based regimens should be avoided because of their suboptimal efﬁcacy and safety (class I, level B) 8
4. DAA combinations of potential use in HCV-infected HCT recipients extrapolated from studies in other patient populations 9
New section and table on drugedrug interactions in HCV-infected HCT candidates and recipients receiving DAAs and conditioning
regimens or immunosuppressive agents
9 Table 4
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Course of HCV infection to 1 year after HCT
HCV infection has hepatic and extrahepatic manifesta-
tions. Hepatic manifestations in HCT recipients in addition to
those seen in immunologically normal hosts include (1) an
increased risk of fatal sinusoidal obstruction syndrome
(previously known as veno-occlusive disease) among pa-
tients with chronic HCV infection who receive sinusoidal
endothelial cell toxins (eg, cyclophosphamide, etoposide,
melphalan, thiotepa, total body irradiation12 Gy) as part of
the conditioning therapy [5]; (2) hepatic inﬂammation
occurring 3 to 6 months after HCT, coincident with immune
reconstitution and discontinuation of immunosuppressive
drugs [5]; (3) liver decompensation among patients who had
cirrhosis at the time of transplant [6,7]; and (4) rarely, fatal
ﬁbrosing cholestatic hepatitis C before day 100 in patients
receiving mycophenolate mofetil [8]. Fibrosing cholestatic
hepatitis is an aggressive form of viral hepatitis caused by
either hepatitis B virus or HCV that causes rapid clinical
deterioration, characterized histologically by extensive
ﬁbroblastic portal-to-portal bridging, ductular proliferation,
cholestasis, high intrahepatocyte viral load, and inﬂamma-
tion [8].
Extrahepatic manifestations of HCV infection after HCT
have been suggested by epidemiologic studies and include
greater 1- to 2-year nonrelapse-related mortality than in
HCV-negative control subjects, including an excess of deaths
related to bacterial infections [6,7]. It is not clear if the higher
mortality is due to HCV per se, the presence of undetected
hepatic ﬁbrosis and portal hypertension, or chronic viral
coinfections (such as hepatitis B virus infection or HIV
infection) at the time of transplant.
Course of HCV infection between 1 and 10 years after HCT
Coincident with immune reconstitution after HCT, serum
alanine aminotransferase (ALT) levels wax and wane in most
HCV-infected patients. The course of this chronic hepatitis is
usually uncomplicated for 10 years after HCT, but, rarely,
patients may progress to cirrhosis. Serum aminotransferase
elevations can be seen in 57% of HCV-infected patientsbetween 5 and 10 years after HCT [5]. In several series no
excess mortality was noted in HCV-infected patients up to
10 years after HCT [5,9,10]. In some patients, however, the
duration of HCV infection before HCT can only be estimated,
and the extent of ﬁbrosis is unknown at the time of HCT; such
patients may experience progressive liver disease that only
becomes apparent after HCT [6,7].
Course of HCV infection 10 to 40 years after HCT
Chronic HCV is the leading cause of cirrhosis after HCT,
and the time to cirrhosis is shorter in patients with chronic
HCV infection who undergo HCT than in patients with
chronic HCV infection who do not undergo HCT [11,12].
About one third of HCV-infected 40-year survivors of HCT
develop end-stage liver disease (cirrhosis, HCC, or disease
requiring liver transplant). HCT recipients who develop end-
stage liver disease can be considered for liver transplant;
living donor liver transplant from the original hematopoietic
cell donor has been described [13,14].Knowledge Gaps
 What is the natural history of HCV in HCT in the era of
current immunosuppressive regimens?
 What are the predictors of liver disease progression in
HCT recipients?
 Do effective antiviral drugs alter the course of HCV-
related ﬁbrosing cholestatic hepatitis, hepatic ﬁbrosis,
and cirrhosis in HCV-infected survivors of HCT?HCV SCREENING IN DONORS OF HEMATOPOIETIC STEM
CELLS, HCT CANDIDATES, AND LONG-TERM SURVIVORS
Sarah P. Hammond, John R. Wingard
Recommendations
 All hematopoietic cell donors should be screened for
HCV within 30 days before cell harvest with FDA-
approved HCV antibody (anti-HCV) and RNA testing in
H.A. Torres et al. / Biol Blood Marrow Transplant 21 (2015) 1870e1882 1873accordance with the Foundation for the Accreditation
of Cellular Therapies (FACT) standards and FDA guid-
ance (class I, level C).
 All HCT candidates should be screened for HCV with
FDA-approved anti-HCV testing (class I, level C).
 All long-term survivors of HCT should be screened for
HCV infection based on the current recommendations
for screening in non-HCT recipients, with special
attention to those with epidemiologic risk factors,
including those transplanted in the era before routine
donor and blood product screening (class I, level C).Evidence Summary
In the general US population, risk-based screening for
HCV infection with anti-HCV testing (with reﬂex HCV RNA
testing for individuals with positive results) is recommended
by the Centers for Disease Control and Prevention [15], US
Preventive Services Task Force [16], and AASLD, IDSA, and
International Antiviral SocietyeUSA [1]. Individuals consid-
ered at high risk include not only intravenous drug users but
also individuals born between 1945 and 1965 [15].
Transmission of HCV from HCV-infected bone marrow
donors to uninfected recipients was ﬁrst documented in the
early 1990s [17]. FACT has issued standards for US centers
performing HCT that include HCV screening of allogeneic
donors within 30 days before stem cell harvest using tests
required by applicable laws and regulations [18]. The FDA has
issued guidelines recommending that such donors be
screened with FDA-licensed antibody and nucleic acid tests
[19]. A positive test result for anti-HCV (using third-
generation tests) in the setting of undetectable serum HCV
RNA indicates past infection (resolved spontaneously or
therapeutically), acute HCV infection during a period of low-
level viremia, or a false-positive test result [1,20].
False-positive anti-HCV tests are more common with
earlier generation testing, especially if conﬁrmation with the
recombinant immunoblot assay was not included in the
method. In such a case the HCV-treating providers should
retest the donor for anti-HCV and HCV RNA to exclude the
presence of active infection and seek guidance from an in-
fectious disease or hepatology expert.
The presence of serum HCV RNA indicates current and
active infection. If the viremia persists for more than
6 months postexposure, the infection is considered chronic
and is not likely to resolve spontaneously.
FACT and FDA guidance on HCT donor screening does not
extend to HCT candidates and recipients. Overall, HCV
screening in HCT candidates establishes a pretransplant
baseline and identiﬁes patients who might beneﬁt from HCV
treatment after transplant. There is usually insufﬁcient time
to complete a course of HCV therapy before HCT. Chronic
HCV can be associated with false-negative anti-HCV test
results in immunosuppressed patients [20], including HCT
recipients [21]. Such patients have a positive serum HCV PCR
test.
In a prospective study in allogeneic HCT recipients from
15 European transplant centers, data on pretransplant HCV
RNA were available for 182 patients, and 11 were found to
have viremia, including 6 anti-HCVenegative patients [21].
In HCT candidates and recipients, screening with HCV RNA
testing in addition to anti-HCV serologic testing is advocated
by many experts (class IIb, level C). In 1 study, 13% of HCV-
infected patients with a positive anti-HCV test result before
HCT had a negative anti-HCV test result after HCT [22].Knowledge Gap
 How frequently are HCT candidates or HCV recipients
seronegative for HCV with third-generation tests
despite serum nucleic acid evidence of active infection?
 What is the most cost-effective algorithm for screening
HCT candidates and recipients?
IMPACT OF HCV INFECTION ON ELIGIBILITY TO DONATE
HEMATOPOIETIC STEM CELLS OR UNDERGO HCT
Harrys A. Torres, John R. Wingard
Recommendations
 HCV infection in donors or potential HCT recipients
should not be an absolute contraindication for HCT
(class I, level C) (Table 3).
 The risk of HCV transmission is extremely low when
seronegative and HCV RNAenegative HCT candidates
receive HCT from donors of hematopoietic stem cells
with positive anti-HCV and undetectable HCV RNA
(class I, level C).
 HCV-infected donors should be assessed for advanced
chronic liver disease and other extrahepatic manifes-
tations of HCV to recommend an optimal management
of their disease (class I, level C).
 HCV-infected donors should be screened for other
coinfections (eg, HIV). HIV-HCVecoinfected individuals
should not be considered as donors for HIV-
seronegative recipients, according to standard HCT
guidelines [4].
 HCV-infected HCT candidates requiring HCT and for
whom there is no alternative donor can proceed with
HCT from a donor also infected with HCV provided the
recipient has full understanding of the potential con-
sequences given the viral characteristics of the donors’
HCV infections (class IIa, level C).
 If the donor is HCV RNA positive and transplantation to
an HCV-infected or -uninfected recipient is considered,
the donor should start antiviral therapy immediately
with the goal of reducing the infectious potential of the
donor, ideally attaining undetectable plasma HCV RNA
in the donor before stem cell harvest (class I, level C).
 Selection of HCV-infected candidates for HCT should be
based on the extent of liver ﬁbrosis and degree of portal
hypertension (class I, level C).Evidence Summary
Donors with positive HCV screening test results
As recommended for the general population [1], donors
(or HCT recipients) found to have positive results for anti-
HCV and negative results for HCV RNA by PCR using an
FDA-approved sensitive HCV RNA test should be informed
they do not have evidence of current (active) HCV infection.
Repeat HCV RNA testing at a later date (eg, 1 to 2 months) is
typically unnecessary but can be performed when there is
strong suspicion of acute infection or in patients with
ongoing risk factors for HCV infection [1].
Up to 100% of infected donors transmit HCV to uninfected
HCT recipients [17]. If no alternative donor is available and if
time does not permit treatment of the infected donor to
eliminate HCV from the infusion product, the use of HCV-
infected hematopoietic cells for an HCV-uninfected recip-
ient is not contraindicated. New DAAs could potentially
provide a virologic cure after HCT in most patients and may
Table 3
Eligibility to Donate Hematopoietic Stem Cells or Undergo HCT according to Different Clinical Scenarios
Clinical
Scenario
Donor
Anti-HCV
Donor
HCV RNA
HCT Candidate/
Recipient Anti-HCV
HCT Candidate/Recipient
HCV RNA
Recommendation for Donor Recommendation for HCT Candidate/Recipient
1 Negative Negative Negative Negative Proceed with stem cell harvest. Proceed with HCT.
2 Negative Positive Negative Negative Proceed with stem cell harvest. When possible, start antivirals
and proceed with cell harvest once HCV PCR is undetectable.*
Proceed with HCT. Monitor HCV RNA managing acute infection
per HCV guidance.y
3 Negative Positive Positive Negative Proceed with stem cell harvest. When possible, start antivirals
and proceed with cell harvest once HCV PCR is undetectable.*
Proceed with HCT. Monitor HCV RNA managing acute infection
per HCV guidance.y
4 Negative Positive Positive Positive Proceed with stem cell harvest.z Proceed with HCT.z Start antiviral therapy, when possible.x
5 Negative Positive Negative Positive Proceed with stem cell harvest.z Proceed with HCT.z Start antiviral therapy, when possible.x
6 Negative Negative Positive Negative Proceed with stem cell harvest. Proceed with HCT.jj
7 Negative Negative Positive Positive Proceed with stem cell harvest. Proceed with HCT. Start antivirals, when possible.x
8 Negative Negative Negative Positive Proceed with stem cell harvest. Proceed with HCT. Start antivirals, when possible.x
9 Positive Negative Negative Negative Proceed with stem cell harvest.jj Proceed with HCT.
10 Positive Positive Negative Negative Proceed with stem cell harvest. When possible, start antivirals
and proceed with cell harvest once HCV PCR is undetectable.*
Proceed with HCT. Monitor HCV RNA managing acute infection
per HCV guidance.y
11 Positive Positive Positive Negative Proceed with stem cell harvest. When possible, start antivirals
and proceed with cell harvest once HCV PCR is undetectable.*,jj
Proceed with HCT.y Monitor HCV RNA managing acute infection
per HCV guidance.y
12 Positive Positive Negative Positive Proceed with stem cell harvest.z Manage infection per HCV
guidance.
Proceed with HCT.z Start antivirals, when possible.x
13 Positive Positive Positive Positive Proceed with stem cell harvest.z Manage infection per
HCV guidance.
Proceed with HCT.z Start antivirals, when possible.x
14 Positive Negative Positive Positive Proceed with stem cell harvest.jj Proceed with HCT. Start antivirals, when possible.x
15 Positive Negative Negative Positive Proceed with stem cell harvest.jj Proceed with HCT. Start antivirals, when possible.z,x
16 Positive Negative Positive Negative Proceed with stem cell harvest.jj Proceed with HCT.jj
* When possible, start antiviral therapy immediately, attaining viral clearance before stem cell harvest to reduce the risk of HCV transmission. If HCT must be done urgently, stem cell harvest from a viremic donor should be
considered.
y Per HCV guidance, monitor HCV RNA (eg, every 4 to 8weeks) for 6 to 12months after the time of infection to determine spontaneous viral clearance versus active HCV. Detectable HCV RNA at 6months after onset of infection
will identify most persons who need HCV therapy (http://hcvguidelines.org/full-report/management-acute-hcv-infection).
z HCV-infected HCT candidates requiring HCT and for whom there is no alternative donor can proceed with HCT from a donor also infected with HCV (see text for details).
x HCV-infected HCT candidates should be started on therapy and should complete HCV therapy before transplant, when possible.
jj HCT donors and candidates with positive anti-HCV in the setting of undetectable HCV RNA should have repeat HCV RNA testing when there is strong suspicion of acute infection or in patients with ongoing risk factors for HCV
infection (see text for details).
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dying from the underlying hematologic malignancy without
the transplant outweighs the risk of acquiring potentially
curable HCV. However, the donor should be assessed for
advanced chronic liver disease per current HCV guidance [1]
as well as extrahepatic manifestations of HCV (eg, lympho-
proliferative diseases) and coinfections (eg, HIV) that might
contraindicate donation (class I, level C) [4].
The risk of transmission of HCV was decreased to nearly
0 if HCV RNA was undetectable at the time of hematopoietic
cell donation [17]. In viremic donors, viral clearance with
DAAs before cell harvest may be attempted if feasible to
reduce the risk of HCV transmission, because most donors
will attain undetectable HCV PCR within 4 weeks of starting
currently available DAAs [4,23,24]. The timing of HCV ther-
apy is further discussed below (see When to Treat HCV
Infection in Donors and Autologous or Allogeneic HCT Can-
didates and Recipients).
HCT candidates with positive HCV screening test results
Similar to what is recommended for donors, HCT candi-
dates with positive test results for anti-HCV in the setting of
undetectable HCV RNA should be evaluated to exclude acute
infection by repeating HCV RNA. HCV-infected HCT candi-
dates requiring HCT and for whom there is no alternative
donor can proceed with HCT from a donor also infected with
HCV, provided the recipient has full understanding of the
potential consequences (class IIa, level C) [5]. The potential
consequences include infections with different genotypes
(eg, genotype 3) or resistance-associated variants (such as
NS5A variants) potentially associated with a higher rate of
virologic failure. Treatment recommendations in HCT can-
didates are further discussed below (see When to Treat HCV
Infection in Donors and Autologous or Allogeneic HCT Can-
didates and Recipients). All individuals (donors and re-
cipients) with HCV infection should be referred to a
practitioner able to provide comprehensive management of
HCV [1].Knowledge Gaps
 Studies are needed to determine the magnitude of risk
for HCV transmission when HCV-infected donors have
achieved undetectable HCV RNA but have not
completed their recommended treatment course.MONITORING HCV IN HCT RECIPIENTS WITH CHRONIC
HCV INFECTION
Harrys A. Torres, Marcos De Lima
Recommendations
 In HCT recipients with chronic HCV infection, ALT level
should be evaluated at entry into care, 2 to 8 weeks
after completion of the conditioning regimen, every 2
to 8 weeks during maintenance chemotherapy or
immunosuppressive treatment, and every 3 to
6 months thereafter (class II, level C).
 In HCT recipients with chronic HCV infection, routine
monitoring of HCV RNA is not recommended. However,
viral load should be considered for patients who have
an unexplained elevation of ALT (class II, level C). HCV
RNA should be measured in all patients at entry into
care, and monitoring of viral load should be performed
in patients receiving HCV treatment according to theAASLD-IDSA HCV guidance (http://www.hcvguidelines
.org/) (class I, level C).Evidence Summary
Acute exacerbation of chronic HCV infection, indicated by
a signiﬁcant elevation of serum aminotransferase levels over
the baseline level in the absence of other potential causes of
acute hepatitis, can occur in both immunocompetent [25]
and immunocompromised cancer patients [26]. However,
there are no standard deﬁnitions for this phenomenon. In a
retrospective study of 308 patients with cancer and chronic
HCV infection, 11% were identiﬁed as having acute exacer-
bation of chronic HCV infection, deﬁned as a 3-fold or greater
increase in serum ALT level from baseline in the absence of
(1) inﬁltration of the liver by cancer, (2) use of hepatotoxic
medications, (3) blood transfusion within 1 month of
elevation of ALT level, or (4) other systemic infections
affecting the liver (including hepatitis A virus, hepatitis B
virus, cytomegalovirus, adenovirus, herpes simplex virus,
varicella-zoster virus, and HIV infections) [26]. In that study,
acute exacerbation (signiﬁcant ALT elevation) of HCV infec-
tion during chemotherapy prompted clinicians to discon-
tinue chemotherapy in nearly half of affected patients [26].
Enhanced HCV replication (also known as HCV reac-
tivation [26]) has been deﬁned as an increase in HCV RNA
viral load of at least 1 log10 IU/mL over baseline after
chemotherapy or immunosuppressive therapy [26] because
chronically infected patients have stable HCV RNA levels that
may vary by approximately .5 log10 IU/mL [27]. The increased
replication of HCV appears to be associated with a more
indolent course than hepatitis B virus reactivation [28]; only
a few reports of deaths have been associated with increased
HCV replication [8,29]. Regrettably, the published data on
simultaneous changes in ALT levels and HCV viral load are
limited and not sufﬁcient for examination of whether a
correlation exists between enhanced viral replication and
hepatocellular injury [26], as has been described for patients
with chemotherapy-induced hepatitis B virus reactivation.
Little is known about acute exacerbation of HCV infection
in HCT recipients, with emerging data after autologous and
allogeneic HCT recently presented [22,30]. However, such
studies should be considered preliminary becausemost were
retrospective analyses of small numbers of patients. In 1
prospective study, aspartate aminotransferase (AST) levels
were compared between HCV-infected and HCV-negative
HCT recipients [5]. A severe acute ﬂare of hepatitis
(AST >10 times the upper limit of normal) developed in 11 of
36 HCV-infected patients (31%) who survived at least 1 year
after HCT but only 6 of 115 HCV-negative patients (5%)
(P < .0001). Data on HCV RNA were not presented; thus, it
was not possible to determine whether the increase in AST
level in patients receiving chemotherapy resulted from
coinfections, drugs, or enhanced HCV replication in the
setting of immunosuppression.
Patients with signiﬁcant ALT elevations (eg, 3-fold in-
crease from the upper limit of normal) should be carefully
evaluated for signs and symptoms of liver insufﬁciency and
for alternative causes of liver injury. HCV-treating physicians
should participate in the diagnostic workup of acute exac-
erbation of HCV to exclude other potential explanations for
ALT increase (eg, inﬁltration of the liver by cancer, hepato-
toxic medications, blood transfusion within 1 month, the
hepatitic presentation of liver graft-versus-host disease
[GVHD], or other systemic infections affecting the liver).
H.A. Torres et al. / Biol Blood Marrow Transplant 21 (2015) 1870e18821876Knowledge Gaps
 Prospective studies are needed to determine the inci-
dence, clinical implications, and outcome of acute
exacerbation of chronic HCV infection in HCT
recipients.
 What is the best strategy for monitoring HCV infection
around the time of HCT?
FIBROSIS ASSESSMENT IN HCV-INFECTED HCT
CANDIDATES AND RECIPIENTS
Maya Gambarin-Gelwan and Mark S. Friedman
Recommendations
 All HCV-infected HCT candidates should undergo
assessment of the stage of liver ﬁbrosis and the pres-
ence of cirrhosis (class I, level C).
 The presence of cirrhosis may affect duration and type
of HCV therapy and will identify patients who need to
be screened for HCC and the presence of esophageal
varices (class I, level C).
 The decision to perform a liver biopsy should be made
only after careful consideration of the risks and beneﬁts
of the procedure (class I, level B).
 Serologic marker panels for detection of ﬁbrosis have
not been studied in HCV-infected HCT candidates, and
their use is not recommended (class IIb, level C).
 Ultrasound-based vibration-controlled transient elas-
tography (FibroScan VCTE; Echosens, Paris, France) has
not been studied in HCT recipients, and thus results
should be interpreted with caution (class II, level C).Evidence Summary
All HCV-infected HCT candidates should undergo assess-
ment of the stage of liver ﬁbrosis and the presence of
cirrhosis (class I, level C). The presence of advanced ﬁbrosis
(Metavir  F3) or cirrhosis (Metavir F4) may have a signiﬁ-
cant impact on HCT eligibility, the choice of conditioning
regimen, HCV therapy, and risk of HCC.
Liver biopsy
Liver biopsy has been the gold standard for histopatho-
logic assessment of ﬁbrosis in patients with chronic HCV
infection, particularly when the stage of ﬁbrosis and pres-
ence or absence of cirrhosis may guide subsequent man-
agement. However, liver biopsy is an imperfect gold standard
because it is associated with sampling limitations and error,
is invasive, and carries a risk of complications. Individuals
with hematologic malignancies requiring HCT may be at
particular risk for complications [31] and often require a
transjugular approach because of severe thrombocytopenia
[32]. The decision to perform a liver biopsy should be made
only after careful consideration of the risks and beneﬁts of
the procedure (class I, level B) [33].
Serologic marker panels for detection of ﬁbrosis
Tests for serologic markers of ﬁbrosis have becomewidely
available in the past several years and are used extensively in
patients with chronic HCV infection. The AST-to-platelet ra-
tio index (APRI) and FIB-4 index (combines platelet count,
ALT, AST, and age) are easy to calculate using data available
on routine laboratory testing and can be used to assess for
presence of advanced ﬁbrosis and cirrhosis. Four commercial
serum marker panels have been validated in the generalpopulation of patients with chronic HCV infection: FibroTest/
FibroSure (LabCorp, Burlington, NC, USA), Hepascore (Quest
Diagnostics, Madison, NJ, USA), FibroSpect (Prometheus
Laboratories, San Diego, CA, USA), and the European Liver
Fibrosis Study Group panel (not available in the United
States). No panel has yet emerged as standard of care or is
FDA approved; however, all 4 panels have demonstrated
accuracy in distinguishing patients with signiﬁcant ﬁbrosis
(Metavir score F2 to F4) from those without signiﬁcant
ﬁbrosis (Metavir score F0 or F1) [34]. Because individual
markers in these panels include aminotransferases, platelets,
coagulation parameters, g-glutamyl transferase, total bili-
rubin, haptoglobin, gamma globulins, and so on, the results
might be unreliable in HCTcandidates and recipients because
of cytopenias, ongoing systemic inﬂammation, drug-related
liver damage, and infection. These panels have not been
studied in candidates for HCT or in HCT recipients, and their
use is not recommended in either population.
Vibration-controlled transient elastography
Ultrasound-based elastography in the form of FibroScan
VCTE was approved by the FDA in April 2013. This procedure
has been endorsed by the AASLD “to be used by clinicians
providing care for patients with liver disease to evaluate liver
ﬁbrosis at the point of care” [35]. VCTE is quick, is done at the
time of the clinic visit, is noninvasive, has good reproduc-
ibility, is relatively inexpensive, and provides information
about a large area of the liver. VCTE has been extensively
studied in patients with chronic HCV infection. In a recent US
multicenter study, VCTE demonstrated a positive predictive
value of 75.6% to 80.8% and a negative predictive value of
55.0% to 84.7% for diagnosis of signiﬁcant ﬁbrosis (F  2) and
an estimated positive predictive value of 41.6% to 60.4% and
negative predictive value of 95.6% to 97.6% for diagnosis of
cirrhosis [36]. VCTE would plausibly be useful for assessment
of advanced ﬁbrosis, particularly to rule out cirrhosis in HCT
candidates and recipients, although these patient pop-
ulations have not been extensively studied [37,38].
Knowledge Gaps
 Reliability of serologic markers of ﬁbrosis and FibroScan
VCTE in predicting the presence of advanced ﬁbrosis
and cirrhosis in HCT candidates and recipients.
 Effect of leukemic inﬁltration of hepatic sinusoids,
lymphoma of the liver, or extramedullary hematopoi-
esis with sinusoidal ﬁbrosis on the accuracy of VCTE.
 Role of VCTE as a predictor of hepatotoxicity in HCT
recipients.
WHEN TO TREAT HCV INFECTION IN DONORS AND
AUTOLOGOUS OR ALLOGENEIC HCT CANDIDATES AND
HCT SURVIVORS
Maya Gambarin-Gelwan, Sergio Giralt,
George B. McDonald
Recommendations
 HCV-infected donors should be evaluated for HCV
therapy and treated before cell harvest to prevent
transmission of HCV to uninfected recipients, if possible
(class I, level C).
 All HCT candidates with HCV infection should be eval-
uated for HCV therapy before the start of conditioning
therapy; after transplant, HCV-infected survivors
should also be evaluated for therapy (class I, level B).
H.A. Torres et al. / Biol Blood Marrow Transplant 21 (2015) 1870e1882 1877 When possible, HCV-infected HCT candidates should be
started on therapy and should complete therapy for
HCV before transplant (class IIa, level C).
 After HCT, the following patients should be treated for
HCVwithout delay: HCV-infected patients who develop
ﬁbrosing cholestatic hepatitis C, patients with cirrhosis
whose condition is deteriorating, and patients who
underwent HCT for HCV-related lymphoproliferative
disorders (class I, level C).
 After HCT, treatment for HCV can be deferred until after
immune reconstitution for patients not meeting the
criteria above (class I, level C).
 All HCV-infected long-term survivors of HCT should be
offered antiviral therapy (class I, level C).
 HCV therapy should be undertaken only with the
intention of completion of the full course of therapy as
deﬁned in the AASLD-IDSA Hepatitis C Guidance
(http://www.hcvguidelines.org/). Treatment interrup-
tion is not recommended (class I, level C).
 IFN-based regimens should be avoided in donors and
HCT candidates/recipients with HCV infection because
of their suboptimal efﬁcacy and safety (class I, level B).
 HCV therapy should be undertaken by providers expe-
rienced inmanagement of HCV inHCT recipients in close
collaboration with transplant teams (class I, level B).
Evidence Summary
Treatment of HCV-infected donors before HCT
Several case reports have described successful prevention
of HCV transmission through treatment of HCV-infected
donors before cell harvest [5,24,39,40]. When there are
oncologic imperatives for moving quickly to transplant, DAAs
should be able to clear extrahepatic HCV from donors more
quickly than IFN and ribavirin can without signiﬁcant toxic
effects on the donor marrow. Once initiated, a full course of
antiviral therapy should be completed in donors based on
the current treatment recommendations for individuals with
HCV infection [1].
The risk of HCV transmission at various time points dur-
ing HCV therapy has not been studied. Plausibly the risk of
transmission should be sharply reduced if serum HCV RNA
levels are below the level of detection for the assay.
Treatment of HCV-infected candidates before HCT and
recipients after HCT
Data are lacking regarding treatment of HCV-infected HCT
candidates. DAA therapy before HCT should be considered.
Prompt treatment of HCV infection after transplant is
urgent for 3 groups: patients with ﬁbrosing cholestatic HCV
[8], patients with cirrhosis whose condition is deteriorating
[41], and patients who underwent HCT for HCV-related
lymphoproliferative disorders [22,42]. It is not known,
however, whether the efﬁcacy of DAA therapy is affected by
dysfunctional immunity after therapy for cancer. It is also not
known whether eliminating HCV before HCT improves the
outcome of transplant by, for example, reducing the risks of
post-HCT fatal sinusoidal obstruction syndrome, liver
decompensation, ﬁbrosing cholestatic hepatitis, or recurrent
lymphoma [43,44]. Once HCV therapy is started in either HCT
candidates or recipients, treatment interruption is not rec-
ommended, because it is associated with increased risk of
treatment failure [2].
The alternative to pre-HCT therapy for HCV is to treat
after HCT using DAAs after immune reconstitution [22].
Although published data are limited on outcomes of DAAtherapy in HCT recipients, SVR rates of 70% to 96% have been
observed in patients who received DAAs during immuno-
suppressive therapy after liver transplant [43,44].
A preliminary observational study suggested that IFN-
sparing regimens were well tolerated and effective in 10
HCT recipients and have potential to improve patient out-
comes [22]. Combination DAA therapy appears to be safe and
effective in HCV-infected allogeneic and autologous HCT re-
cipients after a follow-up period of 6 months after transplant
[22]. Some experts advocate waiting for 6 months after the
transplant to allow tapering of immunosuppression agents
and GVHD prophylaxis, which might result in higher SVR
rates and reduction of drugedrug interactions.
Flare of GVHD that occurs after tapering immunosup-
pressive therapy could be confused for HCV exacerbation
and/or medication toxicity in those receiving antivirals.
Some clinicians may still choose to defer DAA therapy until
immunosuppressive treatment has been discontinued to
avoid drugedrug interactions.
IFN-based regimens should be avoided in donors and HCT
candidates with HCV infection because of their suboptimal
efﬁcacy and safety (class I, level B). Data are not available
regarding the impact of treatment regimens consisting of
ribavirin plus DAA in HCV-infected HCT recipients.
Treatment of HCV-infected long-term HCT survivors
About one third of HCV-infected long-term HCT survivors
develop end-stage liver disease or HCC [11,12]. Thus, all HCV-
infected long-term HCT survivors should be offered DAA
therapy. The rationale for universal treatment of infected
survivors is that it can prevent transmission of HCV, delay the
development of cirrhosis, and reduce long-term conse-
quences of chronic HCV infection, including development of
HCC, extrahepatic manifestations of HCV, and possible need
for liver transplantation.
Knowledge Gaps
 Should all HCV-infected donors and HCT candidates be
treated with antivirals before HCT?
 What is the optimal timing of antiviral therapy for HCT
candidates?
 How effective and safe are DAAs given to HCT candi-
dates or recipients?
 What is the effect of virologic cure of HCV on the risk of
sinusoidal obstruction syndrome and other liver-
related complications of HCT in HCV-infected
individuals?
 Does antiviral therapy prevent post-HCT liver disease
progression and relapse of HCV-associated non-Hodg-
kin lymphoma?
 Does recovery of a full immunologic repertoire after
HCT affect the efﬁcacy of antiviral treatment?
ROLE OF DAA COMBINATIONS IN HCV-INFECTED HCT
RECIPIENTS
Pearlie P. Chong, Mark S. Friedman, Henry Masur
Recommendations
Recommendations by HCV genotype as of August 2015
 For infection with genotypes 1a or 1b HCV, treatment
with one of the following four DAA combinations is
recommended:
(1) Daily daclatasvir and sofosbuvir with or without
ribavirin
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sofosbuvir
(3) Daily ﬁxed-dose combination of ombitasvir, par-
itaprevir, ritonavir, and twice-daily dasabuvir with
or without ribavirin
(4) Daily sofosbuvir plus simeprevir with or without
ribavirin
 For infection with genotype 2 HCV, the preferred
regimen is sofosbuvir plus weight-based ribavirin;
those who cannot tolerate ribavirin should be treated
with daily daclatasvir and sofosbuvir.
 For infection with genotype 3 HCV, treatment with one
of the following DAA combinations is recommended:
(1) Daily daclatasvir and sofosbuvir with or without
ribavirin
(2) Daily sofosbuvir and ribavirin plus weekly pegy-
lated-interferon
 For infection with genotype 4 HCV, treatment with one
of the following the three DAA combinations is
recommended:
(1) Daily ﬁxed-dose combination of ledipasvir and
sofosbuvir
(2) Daily ﬁxed-dose combination of ombitasvir, par-
itaprevir, ritonavir, and ribavirin
(3) Daily sofosbuvir and ribavirin.
 For infection with genotypes 5 or 6 HCV, the preferred
regimen is daily ﬁxed-dose combination of ledipasvir
and sofosbuvir (class IIa, Level B).
 Monotherapy with a DAA is not recommended for any
patient with HCV infection (class III, level A).
 The choice of regimen should be individualized on the
basis of patient-speciﬁc data, including potential drug
interactions.
Treatment considerations in speciﬁc patient populations
 HCT recipients often receive multiple drugs that could
have pharmacologic interactions with DAAs or toxic
effects that overlap with those of DAAs. Treating phy-
sicians should be mindful of potential drug interactions
and/or side effects, although this has not been exten-
sively studied in HCT recipients.
 In patients with mild (creatinine clearance 60 to
89 mL/min) to moderate (creatinine clearance 30 to
59 mL/min) renal impairment, no dosage adjustment is
required for daclatasvir, sofosbuvir plus simeprevir,
ledipasvir plus sofosbuvir, or ombitasvir, paritaprevir,
ritonavir, and dasabuvir (class I, level A). The total daily
dose of ribavirin should be reduced for patients with
creatinine clearance 50 mL/min [45].
 In patients with severe renal impairment (creatinine
clearance 15 to 29 mL/min) or with end-stage renal
disease, safety and efﬁcacy data for DAAs are not
available; treatment can be contemplated after
consultationwith an expert (class IIb, level C) or as new
data in this patient population become available. If
ribavirin is used, dose should be reduced [45].
 Patients coinfected with HIV and HCV should be treated
like HCV-monoinfected patients, except that in-
teractions with antiretroviral medications must be
recognized and managed (class I, level B).
Evidence Summary
DAAs are oral agents that target various HCV-encoded
proteins vital to the replication of the virus. When used incombination, DAAs are capable of curing HCV infection;
DAAs have demonstrated excellent rates of SVR and favorable
safety proﬁles in multiple phase III clinical trials [46-52].
Unfortunately, the efﬁcacy and safety of DAAs in HCV-
infected HCT recipients have not been extensively studied
or documented. The recommendations above are extrapo-
lated from studies in other patient populations. The optimal
therapy for HCV is evolving rapidly and will continue to
evolve as multiple new drugs are approved and as more
studies are reported. The recommendations above should be
compared with the online AASLD-IDSA Hepatitis C Guidance
for the management of HCV infection, which are updated
frequently as new data emerge (http://www.hcvguidelines.
org/news/hcv-guidance).
The choice of DAA regimen and duration of DAA treatment
for HCV-infected HCT recipients should be informed by prior
treatmentexperience,HCVgenotype, and thedegreeofﬁbrosis.
Knowledge Gaps
 Efﬁcacy and safety of various DAA regimens in HCT
recipients.
 Optimal duration of DAA regimens in HCT recipients.
DRUGeDRUG INTERACTIONS IN HCV-INFECTED HCT
CANDIDATES AND RECIPIENTS RECEIVING DAAS AND
CONDITIONING REGIMENS OR IMMUNOSUPPRESSIVE
AGENTS
Patrick J. Kiel
Recommendations
Recommendations for drug-drug interactions as of August
2015
 Physicians should frequently assess for drugedrug
interactions in HCV-infected HCT recipients (class I,
level C).
 HCT candidates should not receive DAAs concomitantly
with the chemotherapy preparative regimen if the
potential for drugedrug interactions exists (class I,
level C).
 In patients receiving tacrolimus concomitantly with
paritaprevir and ritonavir, holding tacrolimus for one
day with an approximate dose reduction of 75% may be
required. Due to the prolonged half-life of tacrolimus
with this combination more frequent blood level
assessment of tacrolimus, such as twice to thrice
weekly, may be indicated. Some patients may even
require intermittent dosing of tacrolimus based on
blood levels. In patients receiving concomitant cyclo-
sporine, increased therapeutic drug monitoring and an
80% decrease of the cyclosporine dose may be required
(class IIb, level B).
 In patients receiving sirolimus concomitantly with
paritaprevir and ritonavir, increased therapeutic drug
monitoring and a decrease of 90% or more in the siro-
limus dose may be required (class IIb, level C).
 Direct acting antivirals simeprevir, sofosbuvir, ledi-
pasvir/sofosbuvir, and daclatasvir are known to
have the least clinically signiﬁcant interactions with
commonly administered immunosuppressive medica-
tions following HCT. In patients with multiple medica-
tion interactions or those in whom it is prudent to
minimize such interactions based on clinical assess-
ment preference may be given to the aforementioned
treatment regimens (class I, level C).
Table 4
DAA Pharmacology and Potential Interactions with Drugs Used in HCT
Antiviral Agent* Metabolism/Elimination Metabolism Effects Transporter Substrate Transporter Effects Drugs with Which DAA Does or May Interact
Protease inhibitors
Boceprevir CYP3A4, aldoreductase Inhibits CYP3A4 P-gp Potentially inhibits P-gp Increase azoles, CSA, tacrolimus, sirolimus,
etoposide, Cy levels
Paritaprevir
with ritonaviry
CYP3A4, CYP3A5 Inhibits CYP3A4,
UGT1A1
ABCG2, OATP1B1/3, P-gp Inhibits ABCG2, OATPB1/3 Increase azoles, CSA, tacrolimus, sirolimus,
etoposide, Cy levels
Simeprevir CYP3A4 Inhibits CYP1A2,
intestinal CYP3A4
OATP1B1/3, P-gp Inhibits OATP1B1/3, P-gp Increase azoles, CSA, tacrolimus, sirolimus,
etoposide, Cy levels
Telaprevir CYP3A4 Inhibits CYP3A4 OATP1B1, OATP2B1, P-gp Inhibits OATP1B1, OATP2B1, P-gp Increase azoles, CSA, tacrolimus, sirolimus,
etoposide, Cy levels
Ritonaviry CYP3A4, CYP2D6 Inhibits CYP3A4 P-gp Inhibits ABCG2 Increase azoles, CSA, tacrolimus, sirolimus,
etoposide, Cy levels
NS5A inhibitor
Daclatasvir CYP3A4 No data P-gp Inhibitor of ABCG2, OATP1B1, P-gp Increase CSA, tacrolimus levelsz
Ledipasvir Oxidized by unknown mechanisms N/A ABCG2, P-gp inhibits ABCG2, P-gp Increase CSA, tacrolimus levels
Ombitasvir Amide hydrolysis, then oxidation Inhibits UGT1A1 ABCG2, P-gp substrate only Unknown
Nonnucleos(t)ide polymerase
inhibitor
Dasabuvir CYP2C8 (primary), CYP3A4, CYP2D6 Inhibits UGT1A1 ABCG2, P-gp Inhibit ABCG2 CYP2D6 inhibitors increase dasabuvir
Nucleos(t)ide polymerase
inhibitor
Sofosbuvir Extensive hepatic metabolismx to
active moiety GS-461203, then most
is renally eliminated
N/A ABCG2, P-gp Substrate only Unknown
Nucleoside analog
Ribavirin Unknown metabolism, 60% renal
elimination
N/A N/A N/A Increase myelotoxicity with azathioprine
P-gp indicates P-glycoprotein; OATP1B1/3, organic anion-transporting polypeptides 1B1 and 1B3; OATP2B1, organic anion-transporting polypeptides 2B1; ABCG2, ATP-binding cassette subfamily Gmember 2; CSA, cyclosporine
A; Cy, cyclophosphamide; N/A, not applicable.
* Boceprevir and telaprevir are no longer available in the United States but are still in use in other countries.
y Ritonavir is used to boost plasma concentrations of paritaprevir.
z Based on the results of drug interaction trials, no clinically relevant changes in exposure were observed for cyclosporine or tacrolimus with concomitant use of daclatasvir [52].
x Metabolic pathway involves hydrolysis of carboxyl ester moiety catalyzed by human cathepsin A or carboxylesterase 1 and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 followed by phos-
phorylation by the pyrimidine nucleotide biosynthesis pathway.
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The introduction of novel antiviral agents in the treat-
ment of HCV has not eliminated the risk of drug interactions.
Physicians should frequently assess for drugedrug in-
teractions in HCV-infected HCT recipients. Many interactions
may not be adequately documented but rather may have to
be inferred on the basis of the isoenzymes responsible for
drug metabolism. Current databases (eg, http://www.hep-
druginteractions.org) should be consulted along with the
product prescribing information to ensure the safety of
concomitantly prescribed medications such as acid reducers,
antidepressants, antihypertensives, phosphodiesterase in-
hibitors, novel oral anticoagulants, macrolide antibiotics,
triazoles, and HMG CoA inhibitors [1]. However, these da-
tabases lack documentation of potential interactions be-
tween DAAs, commonly prescribed immunosuppressive
agents, and chemotherapy. The pharmacology of DAAs and
potential drugedrug interactions between DAAs and
chemotherapy or immunosuppressive agents used in pa-
tients undergoing HCT are summarized in Table 4 [53-58].
Drugedrug interactions can be pharmacokinetic, result-
ing in changes in drug concentrations, or pharmacodynamic,
resulting in additive, synergistic, or antagonistic effects on
efﬁcacy or toxicity. Metabolism by CYP450 enzyme, specif-
ically the CYP3A4 isoform, is the major metabolic pathway of
approved HCV therapies, including DAAs. Membrane trans-
porters are also implicated in clinically relevant drugedrug
interactions and may include P-glycoprotein, organic anion
transporting polypeptides, and the ATP-binding cassette
subfamily G member 2. Membrane transporters and the CYP
isoenzymes can be induced or inhibited.
The pharmacologic targets of the novel DAAs include NS3/
NS4A protease inhibitors, NS5A inhibitors, and NS5B poly-
merase inhibitors. The protease inhibitors (paritaprevir,
simeprevir, telaprevir, and boceprevir) prevent the NS3 viral
protease from cleaving the enzymes responsible for viral
replication. All 5 agents undergo CYP3A4metabolism and are
affected by inducers (ie, phenytoin, rifampin, carbamazepine,
and phenobarbital) and inhibitors (ie, posaconazole and
voriconazole) [18,54-58].
The protease inhibitors may also increase serum con-
centrations of chemotherapy or immunosuppressive agents
commonly used for HCT that are substrates of CYP3A4,
including cyclophosphamide, etoposide, tacrolimus, cyclo-
sporine, and sirolimus. Paritaprevir is administered
concomitantly with ritonavir, a potent CYP3A4 inhibitor, as a
“boosting” agent and will also interfere with other CYP3A4
and CYP2D6 metabolized medications. Thiotepa is an in-
hibitor of CYP2B6 and has no interactions with DAAs.
The NS5A inhibitors (daclatasvir, ledipasvir, and ombi-
tasvir) inhibit NS5A viral RNA replication and virion assem-
bly. Daclatasvir is metabolized via CYP3A4, whereas
ledipasvir and ombitasvir undergo oxidative metabolism
[52,55,58]. Ledipasvir is an inhibitor and a substrate of in-
testinal P-glycoprotein; inducers of P-glycoprotein (ie, St.
John’s wort, rifabutin, phenobarbital) that are coadminis-
tered may lead to reduced plasma concentrations and ther-
apeutic effects of ledipasvir [58].
The polymerase inhibitor sofosbuvir is renally eliminated,
whereas dasabuvir is metabolized via CYP2C8 (major
pathway), 3A4, and 2D6 [55,58]. Sofosbuvir is a substrate of
intestinal P-glycoprotein, and inducers of P-glycoprotein (ie,
St. John’s wort, rifabutin, phenobarbital) that are coad-
ministered may lead to reduced plasma concentrations and
therapeutic effects of sofosbuvir [58].Immunosuppression with cyclosporine, tacrolimus, and
sirolimus is commonafterHCT.Cyclosporinehasbeenobserved
to increase sofosbuvir area under the curve (AUC) , but the
interaction was not clinically signiﬁcant in healthy volunteer
[59]. Simeprevir can increase cyclosporine and tacrolimus AUC
by19%and17%, respectively [60]. Telaprevir increases thedose-
normalized exposure AUC0-N values of cyclosporine and
tacrolimus approximately 4-fold and 70-fold, respectively [61].
Themean half-life of cyclosporinewas increased from12 hours
to 42.1 hours, and the mean half-life of tacrolimus was
increased from 40.7 hours to 195 hours. Boceprevir increases
the AUC0-N values of cyclosporine and tacrolimus approxi-
mately 3-fold and 17-fold, respectively [62]. Experience with
dosing of immunosuppressive agents after liver transplant
concomitantly with telaprevir or boceprevir plus IFN and
ribavirin suggests an empiric dose reduction of approximately
75% for tacrolimus and 35% for cyclosporine [63,64]. Telaprevir
and boceprevir are no longer available in the United States.
Sirolimus plasma concentrationswith the use of DAAs have not
been prospectively evaluated, but case reports in patients with
liver transplant would suggest a 90% dose decrease [64].
Co-administration of ombitasvir, paritaprevir, ritonavir
and dasabuvir with cyclosporine or tacrolimus results in
clinically signiﬁcant increased immunosuppression levels,
presumably from the protease inhibitors.65 Cyclosporine
AUCN is increased 5.8 fold while the half-life may increase
from 7.3 to 25 hours. Due to this increased exposure and
decreased clearance it is recommended to empirically
decrease the cyclosporine dose by 80% and potentially dosing
on a daily basis followed by more frequent assessment of
blood levels. Tacrolimus AUCN is increased 57 fold while the
half-life may increase from 32 to 232 hours. When co-
administering ombitasvir, paritaprevir, ritonavir and dasa-
buvir with tacrolimus, then tacrolimus should be held on at
least on the ﬁrst day of DAA dosing and may require a 75%
dose decrease.55 Tacrolimus and associated laboratory
monitoringmay require twice or thriceweeklymonitoring as
published dosing experience with this combination is
limited to healthy volunteers and patients with a liver
transplant suggesting that intermittent dosing based on
blood levels may be required.55,65,66
When a calcineurin inhibitor or sirolimus is used with a
protease inhibitor, it is reasonable to empirically reduce the
dose of the immunosuppressive agents and monitor their
levels more frequently because of major CYP3A4 and P-glyco-
protein drugedrug interactions. Formal dosing recommenda-
tions and the degree of dose adjustments in HCT recipients are
conservatively estimated because pharmacokinetic studies
have not evaluated dosage changes; studies are limited to
healthy volunteers or solid organ transplant recipients.
Knowledge Gap
 Studies are needed on the potential interactions be-
tween DAAs, immunosuppressive agents, and chemo-
therapy used in HCT candidates.
OVERLAP BETWEEN TOXIC EFFECTS OF DAAs AND OF
CONDITIONING REGIMENS AND SYMPTOMS OF GVHD IN
HCV-INFECTED HCT CANDIDATES AND RECIPIENTS
Sarah P. Hammond, Sergio Giralt
Recommendations
 No recommendations can be made regarding overlap
between the toxic effects of DAAs and the toxic effects
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because evidence is lacking.Evidence Summary
Historically, treatment of HCV with IFN and ribavirin in
allogeneic HCT recipients was carried out with some trepi-
dation because of concerns about exacerbation of GVHD,
anemia, and neutropenia. However, a relatively large cohort
study showed no overall increase in GVHD among allogeneic
HCT recipients treated with IFN with or without ribavirin
after transplant, and there was a trend toward a decrease in
the risk of severe liver complications after transplant with
HCV treatment [67].
Because DAAs have been approved by the FDA for treat-
ment of HCV only since 2011, information about the use of
these agents in allogeneic HCT candidates and recipients is
largely anecdotal [1]. This paucity of data limits under-
standing of the overlap between the toxic effects of DAAs and
the toxic effects of HCTconditioning regimens and symptoms
of GVHD.
The ﬁrst DAAs approved to treat genotype 1 HCV infec-
tion, telaprevir and boceprevir, were both associated with
toxic effects that could bemistakenly attributed to GVHD (eg,
rash) or HCT conditioning regimens (eg, anemia) in the
appropriate clinical context [68,69]. However, the availability
of potent alternatives with fewer side effects to treat geno-
type 1 HCV has made telaprevir and boceprevir less desirable
than other agents (both telaprevir and boceprevir have been
removed from the US market) [47,48]. Simeprevir, a more
recently approved protease inhibitor, can cause mild hyper-
bilirubinemia, which could also be mistakenly attributed to
GVHD in the appropriate clinical context, but this effect is
typically transient [70].
In general, the observed toxic effects of newer DAAs
approved for clinical use outside of clinical trials are minimal
compared with the toxic effects of IFN, ribavirin, and even
telaprevir and boceprevir. Further studies and more post-
marketing experiencewith thesemedications, particularly in
patients with hematologic disorders and patients who have
undergone HCT, will be crucial for predicting potential toxic
effects unique to HCT recipients.
Knowledge Gap
 The toxicity proﬁle of DAAs in HCT recipients, including
the toxic effects on progenitor cells.
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